Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycaemic control in patients with type 2 diabetes. It works by stimulating the pancreas to produce more insulin when blood sugar levels are high. Vildagliptin is a primary component in many modern, cost-efficient generic diabetes treatments in the UK. We provide secure access to high-quality medications containing Vildagliptin to help you manage your condition.
Vildagliptin belongs to a class of medicines known as DPP-4 inhibitors. It helps control blood-sugar levels by influencing the body’s natural insulin response. The active ingredient appears in several UK-available products, including the branded tablet Vsmall.
In the United Kingdom, Vildagliptin is supplied as the generic substance and as the branded tablet Vsmall. Vsmall is usually offered in film-coated tablets that can be taken once or twice daily, depending on the product’s specific formulation. Different strengths are marketed to suit individual treatment plans, and the medication may be found combined with other glucose-lowering agents in some fixed-dose combinations.
These uses are based on the medication’s approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Vildagliptin blocks an enzyme called dipeptidyl-peptidase-4 (DPP-4). When DPP-4 is inhibited, two natural hormones that stimulate insulin release and reduce glucose production stay active longer. This results in a modest increase in insulin after meals and a slight decrease in the amount of sugar the liver releases, helping to keep overall blood-sugar levels within the desired range. Effects are usually noticed within a few days of regular use.
These reactions are typically short-lived and resolve without medical intervention.
If any of these occur, seek urgent medical assistance.
For a full list of possible interactions, refer to the product’s patient information leaflet or the specific medication page for Vsmall.
Store Vsmall tablets in a dry place below 25 °C, away from direct sunlight and out of reach of children. The medication is generally prescribed for short-term initiation and then reviewed regularly to decide if continued use is appropriate. Remember that each Vildagliptin-containing product may have its own instructions; always follow the information that comes with the specific medicine you receive.
DPP-4 inhibitor: A drug that blocks the enzyme dipeptidyl-peptidase-4, helping the body release more insulin after meals.
Blood-glucose control: The process of keeping blood-sugar levels within a target range.
Pancreatitis: Inflammation of the pancreas, a condition that can affect digestion and blood-sugar regulation.
This article offers general educational information about Vildagliptin as an active substance used in various medicines. Its purpose is to help patients better understand the ingredient and the conditions it is used to treat. It is not a substitute for professional medical advice or for the specific instructions provided with individual products. Medicines containing Vildagliptin may differ in formulation, strength, and directions for use. Always consult the labeling of your particular medication and follow your healthcare provider’s guidance for complete information on proper use, dosage, and safety.
